Sino Biopharm (01177.HK) opened high at 0.76% today, with a maximum of 2.72 yuan, rising 3% at one point. The current price is 2.71 yuan, up 2.65%, with a turnover of 18.2835 million shares involving 49.1681 million yuan.

The company's "liraglutide injection" (trade name: Bydureon) has been approved for marketing by the China National Medical Products Administration for controlling blood sugar in type 2 diabetes patients in adults. The company stated that in addition to liraglutide, it is also developing semaglutide, which is currently in phase III clinical trials and has the potential to bring good news to hundreds of millions of diabetes and obesity patients in China. (cy/w)

~